Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drugstore.com

This article was originally published in The Tan Sheet

Executive Summary

Online retailer's net sales increase 41% to $84.3 mil. with a net loss of $6.3 mil. in the firm's third quarter, drugstore.com reports Oct. 26. Over-the-counter segment revenues rose 37% to $35.2 mil. due in part to a wider array of nutritional products. CEO Dawn Lepore says the firm has made "encouraging progress in a number of key areas despite a critical management transition and a seasonally challenging period." Lepore took over as CEO in September (1"The Tan Sheet" Sept. 27, 2004, In Brief)...

You may also be interested in...



Drugstore.com leadership

Online retailer appoints Dawn Lepore as CEO, effective Oct. 11. Lepore currently is VP-technology, operations and administration at Charles Schwab, a member of Schwab's executive committee and a trustee of SchwabFunds; she will relinquish all of her Schwab positions when she joins Drugstore.com. Drugstore.com board member Melinda Gates says Lepore "brings a great deal of respect and depth from the e-commerce industry as both a leader and an innovator," having designed Schwab's "entire technology platform" and played a "key role" in that firm's online brokerage business. Lepore replaces interim CEO and current CFO Robert Barton, who took over after Kal Raman stepped down in June (1"The Tan Sheet" June 14, 2004, In Brief)...

GSK Aims To Launch 13 Blockbusters In Five Years

GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.

FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu

The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.

Topics

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel